hrp0094p2-206 | Fat, metabolism and obesity | ESPE2021

HOMA-IR in obese children with BMI ≥2.5SDS, but not <2.5SDS, differ significantly from normal weight children

Leka-Emiri Sofia , Dikou Maria , Evangelopoulou Catherine , Kafetzi Maria , Petrou Vasilios , Vlachopapadopoulou Elpis , Michalacos Stefanos ,

Objective: Compare HOMA-IR between obese and normal weight children.Methods: 292 children (156 females), BMI (≥0SD), Tanner stage 1/>2: 163/129, divided in four groups (Group 1: 0SD<BMI<2SD, Group 2: 2SD≤BMI<2.25SD, Group 3: 2.25SD≤BMI<2.5SD, Group 4: BMI≥2.5SD) were analyzed retrospectively from the medical records. Age, sex, fasting blood glucose and insulin as well as the ho...

hrp0094p2-223 | Fat, metabolism and obesity | ESPE2021

Absence of dyslipidemia in obese children with BMI ≥2.5SDS and similar lipidemic profile to those with BMI <2.5SDS or normal weight

Leka-Emiri Sofia , Dikou Maria , Evangelopoulou Catherine , Kafetzi Maria , Petrou Vasilios , Vlachopapadopoulou Elpis , Michalacos Stefanos ,

Objective: Compare triglycerides, total cholesterol, HDL and LDL levels between obese and normal weight children.Methods: 547 children (286 females) with BMI (≥0SD) were divided in four groups (Group 1: 0SD<BMI<2SD, Group 2: 2SD≤BMI<2.25SD, Group 3: 2.25SD≤BMI<2.5SD, Group 4: BMI≥2.5SD) and analyzed retrospectively from the medical records. Age, sex, BMI z-score, triglycerides, tot...

hrp0097p1-497 | GH and IGFs | ESPE2023

First-year response to growth hormone (rGH) treatment and assessment of iGRO software for the prediction of growth velocity.

Kosteria Ioanna , Atnanasouli Fani , Dikaiakou Eirini , Leka-Emiris Sofia , Vlachopapadopoulou Elpis-Athina

Objectives: Response to rGH during the first year of treatment is considered indicative of its effectiveness for the improvement of final height. The iGRO software assesses the response to rGH in children with idiopathic growth hormone deficiency (IGHD) or small for gestational age (SGA) based on age, gender, gestational age, birthweight, rGH dose, maximal GH during stimulation tests, as well as weight and height measurements on follow-up visits. The aim was t...

hrp0097p1-563 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Clinical and analytical presentation of central precocious puberty according to age: a 20-year retrospective study

Luísa de Carvalho Ana , Matilde Carvalho Rita , Martins Sofia , Antunes Ana , Miguel Gomes Maria

Introduction: Central Precocious Puberty (CPP) results from the premature activation of the hypothalamic-pituitary-gonadal axis. Is defined by the onset of secondary sexual characters before 8-years-old in girls and 9-years-old in boys. It’s associated with accelerated growth and advanced bone maturation and can lead to early epiphyseal fusion and reduced final height at adult age.Aims: To evaluate and compare the ...

hrp0097p2-21 | Growth and Syndromes | ESPE2023

Schaaf-Yang syndrome: Report of two cases

Rampi Gabriela , Berger Malena , Cecchi Griselda , Schneider Claudia , Juarez Peñalva Sofia , Forrester Andrea

Schaaf-Yang syndrome (SYS) is a genetic disorder caused by truncating pathogenic variants in the paternal allele of the maternally imprinted, paternally expressed gene MAGEL2, located in the Prader-Willi critical region 15q11-15q13. SYS is a neurodevelopmental disorder that has clinical overlap with Prader-Willi Syndrome in the initial stages of life, being the intellectual disability, developmental delay, autism spectrum disorder, neonatal hypotonia, infantile feeding problem...

hrp0097p2-95 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Short-term impact of therapy with GNRH analogues on the growth of female children with central precocious puberty: a retrospective study of the last 20 years

Luísa de Carvalho Ana , Carvalho Adriana , Martins Sofia , Antunes Ana , Miguel Gomes Maria

Introduction: Since the 1980s, long-acting gonadotropin-releasing hormone analogues (GnRHa) have been the standard treatment for central precocious puberty (CPP).Aims: To evaluate the short-term response (at 6 and 12 months) of treatment with GnRHa in female children diagnosed with CPP, regarding growth, bone maturation (Greulich and Pyle method), predicted adult height (PAH) and pubertal development (Tanner stages)....

hrp0097p1-247 | Fat, Metabolism and Obesity | ESPE2023

Th17 lymphocytes and peripheral complete blood count alterations in obese children

Artemniak-Wojtowicz Dorota , M. Kucharska Anna , Stelmaszczyk-Emmel Anna , Majcher Anna , Rumińska Małgorzata , Pyrżak Beata

Introduction: Obesity is considered one of the most common chronic diseases worldwide which is associated with chronic, low-grade, sterile inflammation. It leads to variable changes in metabolic and hormonal homeostasis. The aim of our study was to evaluate the impact of obesity associated chronic inflammation on peripheral complete blood count alterations.Material and Methods: 27 overweight/obese and 15 normal-weight ch...

hrp0095p2-114 | Fat, Metabolism and Obesity | ESPE2022

Leptin receptor deficiency: a case report

Zufarova Yulduz , Kolodkina Anna , Tiulpakov Anatoly

Background: Leptin receptor deficiency leads to severe early-onset obesity and pituitary dysfunction. Here we present the first case of monogenic obesity due to a novel mutation in LEPR gene in Russia.Case report: 16-year-old female patient was admitted to our hospital with morbid obesity and primary amenorrhea. She was born at term with a birth weight of 3360 g to non-consanguineous parents. She had a mild deve...

hrp0095p2-217 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

A rare case of Cystic fibrosis and Pallister-Hall syndrome combination in a 3-year-old boy

Khabibullina Dina , Novokreshhennyx Evgeniya , Kolodkina Anna

Introduction: Pallister-Hall syndrome (PHS) is a rare disease with autosomal dominant pattern of inheritance caused by CHD7 gene mutation and characterized by epiglottis malformation, polydactyly or oligodactyly, hypothalamic hamartoma and visceral abnormalities. Central precocious puberty is the most common endocrine abnormality detected in PHS. Regardless isolated growth hormone deficiency, pan hypopituitarism and genitourinary malformation are reported in P...

hrp0092p3-132 | Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia) | ESPE2019

Recurrent Apnea in a Boy Suffering from Congenital Hyperinsulinism in the Course of Diazoxide Treatment

Nowaczyk Jedrzęj , Kucharska Anna

Congenital hyperinsulinism (CHI) is rare disease which prevalence is estimated as 1:2500 to 1:50000 born newborns. Main reason of the disease are genetic mutations in genes responsible for regulation of insulin secretion. First line treatment is diazoxide therapy.Our patient was diagnosed with CHI at the age of 2 months. Biochemical tests prooved diagnosis of CHI. He presented lack of negative feedback and secreted pathologic amount of insulin – dur...